Quest Diagnostics (DGX) Investor Day 2025 summary

Market outlook and growth strategy

• Clinical lab market remains strong, driven by demographic shifts, chronic disease, and diagnostic innovation, with U.S. market growth at 2% and Canada growing faster due to population and aging trends.

• Strategic focus on expanding health plan access, geographic reach, and partnerships with large physician groups, health systems, and enterprise accounts to achieve above-market growth rates in both U.S. and Canada.

• Expanding in high-growth areas such as consumer-initiated testing, life sciences, and analytics, aiming for over 20% combined CAGR in these segments.

• Leveraging recent acquisitions, including eight completed in 2024, expected to generate ~$1B in annualized revenue, and expanding presence in the $5B Canadian market via LifeLabs acquisition.

• Balanced capital deployment with majority of free cash flow returned to shareholders, ongoing dividend growth, and disciplined M&A focused on accretive, high-ROI deals.

Innovation and advanced diagnostics

• Investments in five key clinical areas: oncology, cardiometabolic health, women's/reproductive health, brain health, and autoimmune disorders, with advanced diagnostics expected to reach $1.2B+ revenue by 2027.

• Launch of Haystack MRD for oncology, ADDETECT for Alzheimer's, and proprietary tests like HDL function and insulin resistance panels, driving earlier diagnosis and therapy monitoring.

• AI and automation integrated across lab operations, digital cytology, logistics, and billing, improving productivity, quality, and customer experience.

• Project Nova to modernize order-to-cash systems, streamline processes, and enable enterprise-wide IT upgrades, with benefits ramping from 2027 and completion by 2032.

• Collaboration with Google Cloud and strategic partnerships, such as with Fresenius Medical Care, to enhance data management, analytics, and access to new markets.

Operational excellence and productivity

• Invigorate program and other initiatives target 3% annual productivity and cost savings through standardization, digitization, and AI-driven process improvements.

• Automation in labs (e.g., Roche P612, cobots, digital cytology) and logistics (dynamic route optimization) reduces manual labor, increases throughput, and lowers costs.

• Enhanced digital patient journey, including pre-visit data collection, real-time result notifications, and mobile-friendly billing, boosts satisfaction and reduces call center volume.

• Employee engagement initiatives, targeted retention, and development programs have reduced attrition by over five percentage points in two years.

• Customer and physician satisfaction scores remain high, with patient NPS at 74 and physician satisfaction at 86%.